Göhring U J, Aslan-Schadwinkel Y, Scharl A
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität zu Köln.
Geburtshilfe Frauenheilkd. 1993 Sep;53(9):625-9. doi: 10.1055/s-2007-1023599.
In a retrospective study, paraffin-embedded tissues from 110 primary T1 breast carcinomas (tumour diameter < or = 2 cm) were examined for the presence of the Her-2/neu encoded oncoprotein p185neu, using an immunohistochemical technique. Primary surgical therapy revealed no node involvement in 76 cases. These patients did not receive an adjuvant systemic therapy. 25% of tumours were positive for p185neu. Expression of the oncoprotein was inversely correlated to oestrogen receptor status (p < 0.05). In patients with lymph node metastases and poorly differentiated tumours, the incidence of p185neu was higher than in node negative and/or well differentiated carcinomas. However, this finding was statistically not significant. No correlations were found between the detection of the oncoprotein and age, menopausal and progesterone receptor status. The median follow-up is 85 months. In patients without lymph node metastases (n = 76), presence of the oncoprotein was significantly correlated to a shorter relapse-free and/or overall survival (p < 0.05). No such correlation was found for 34 patients with lymph node involvement. Expression of p185neu seems to mark a group of T1N0 breast cancer patients, which is at high risk and might benefit from an adjuvant therapy.
在一项回顾性研究中，采用免疫组化技术，对110例原发性T1期乳腺癌（肿瘤直径≤2cm）的石蜡包埋组织进行检测，以确定是否存在Her-2/neu编码的癌蛋白p185neu。初次手术治疗显示，76例患者无淋巴结受累。这些患者未接受辅助性全身治疗。25%的肿瘤p185neu呈阳性。癌蛋白的表达与雌激素受体状态呈负相关（p<0.05）。在有淋巴结转移和低分化肿瘤的患者中，p185neu的发生率高于无淋巴结转移和/或高分化癌的患者。然而，这一发现无统计学意义。癌蛋白的检测与年龄、绝经状态和孕激素受体状态之间未发现相关性。中位随访时间为85个月。在无淋巴结转移的患者（n=76）中，癌蛋白的存在与无复发生存期和/或总生存期较短显著相关（p<0.05）。在34例有淋巴结受累的患者中未发现此类相关性。p185neu的表达似乎标志着一组T1N0期乳腺癌患者，这组患者风险较高，可能从辅助治疗中获益。
